Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Blue Ridge Pharmacy and Compounding Center
WARNING LETTER
•Blue Ridge Pharmacy and Compounding Center•October 23, 2013

Blue Ridge Pharmacy and Compounding Center – FDA Warning Letter, Oct 23, 2013

Record Details

The FDA issued a Warning Letter to Blue Ridge Pharmacy and Compounding Center following an October 15-23, 2013 inspection. The firm produced drug products without valid prescriptions for individually-identified patients, rendering them misbranded (FDCA 502(f)(1)) and ineligible for statutory exemptions. Serious deficiencies in sterile drug production led to adulteration (FDCA 501(a)(2)(A)) due to insanitary conditions. Specific issues included non-sterile disinfectants/gloves, lack of sporicidal agents, inadequate instrument disinfection, no environmental monitoring, and an unclassified, carpeted glove box room lacking HEPA filtered air and cleanable surfaces. Significant Current Good Manufacturing Practice (CGMP) violations also caused adulteration (FDCA 501(a)(2)(B)). These included inadequate cleaning/disinfection (21 CFR 211.42(c)(10)(v)), lack of validated aseptic procedures (21 CFR 211.113(b)), insufficient environmental monitoring (21 CFR 211.42(c)(10)(iv)), poor equipment maintenance (21 CFR 211.42(c)(10)(vi)), no final product testing (21 CFR 211.167(a)), inadequate stability testing (21 CFR 211.166(a)), deficient air supply (21 CFR 211.42(c)(10)(iii)), and inappropriate personnel clothing (21 CFR 211.28(a)). The firm recalled sterile products and ceased sterile compounding. FDA recommended a comprehensive assessment and full 21 CFR Part 211 CGMP implementation before resuming production. A written response detailing corrective actions or confirming cessation was required within fifteen working days, with warnings of potential legal action.

Company
Blue Ridge Pharmacy and Compounding Center
Inspection date
October 23, 2013
Product type
Drugs
Office
Atlanta District Office
People
  • Ingrid A. Zambrana
  • Marie Mathews
View Company Profile

ID · adcf4295-881a-4658-970f-7388dda146f2

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 352(f)(1)21 U.S.C. 351(a)(2)(A)21 U.S.C. 331(k)21 CFR 21021 CFR 21121 CFR 211.42(c)(10)(v)21 CFR 211.113(b)21 CFR 211.42(c)(10)(iv)

Full citation text and observation details available on the Dashboard.

Other documents for Blue Ridge Pharmacy and Compounding Center
  • 483 - 2013-10-23October 23, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Blue Ridge Pharmacy and Compounding Center
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.